 |
Overview
RESPeRATE, the
breakthrough non-drug medical device to lower high blood
pressure, is now available without a prescription to the
50 million Americans with high blood pressure.
RESPeRATE’s remarkable, patented technology
interactively guides you through therapeutic breathing
exercises that have been clinically proven to lower high
blood pressure – with no side effects.
Read how and why RESPeRATE lowers blood pressure,
view a product demonstration, receive detailed clinical
information you can share with your doctor and much
more.
Clinical achievements for RESPeRATE,
our non-drug medical device for lowering blood pressure,
include:
- The first and only medical device indicated for
the adjunctive treatment of hypertension.
- 14/9 mmHg average sustained blood pressure
reductions within eight weeks.
- No side effects, no drug interactions.
- Results of six clinical trials published in
peer-reviewed medical journals [1-5].
RESPeRATE
Reduces Severity of Hypertension


Each
point represents the office systolic BP of the
141 patients in the RESPeRATE
treatment group
How RESPeRATE Works
|
RESPeRATE’s
patented interactive technology safely and
effectively guides patients through breathing
exercises that have been clinically proven to reduce
blood pressure.
RESPeRATE enables
patients to effortlessly slow their breathing rate
from the normal range of 14 to 16 breaths per minute
to the “therapeutic pattern” of under 10 breaths per
minute with prolonged exhalation.
|
|
These breathing exercises are
difficult to perform properly without continuous
individualized coaching. RESP eRATE
provides this individualized coaching, in the
comfort of your patient’s home.
Since each patient’s breathing rate and pattern change
constantly, RESPeRATE’s
patented technology automatically customizes the
breathing exercises to the patient’s breathing rate
and pattern at the beginning and throughout the
exercise. During each exercise,
RESPeRATE
constantly monitors and analyzes the patient’s
breathing rate and pattern to create a personalized
melody composed of two distinct tones – one tone for
inhalation, one for exhalation. As patients listen to
the melody and synchronize their breathing with these
tones, RESPeRATE
gradually prolongs the exhalation tone, thereby
guiding the users to the slower therapeutic breathing
zone.
While breathing returns to normal after each
session, the beneficial effects on the blood pressure
accumulate. Within 8 weeks of use (15 minutes at least
3-4 times per week), a significant and sustained
reduction in blood pressure can be achieved.
Why RESPeRATE Works
RESPeRATE’s
unique therapeutic breathing exercises result in
significant and sustained reductions in blood pressure
by reducing the body’s sympathetic neural activity and
relaxing the muscles surrounding small blood vessels,
allowing blood to flow more freely. In addition,
RESPeRATE has been
shown to enhance baroreflex sensitivity following the
exercise [1]. RESPeRATE’s
patented method of interactive device-guided breathing
is key to maximizing the effectiveness of the therapy as
it allows patients to “effortlessly” reach the
therapeutic breathing pattern.
| [1] |
Schein M, Gavish B, Herz M
et al. "Treating hypertension with a device that
slows and regularizes breathing: a randomized
double-blind controlled study." J Human Hyperten
2001; 15(4): 271 - 278. |
| [2] |
Grossman E, Grossman A,
Schein MH, Zimlichman R, Gavish B "Breathing-control
lowers blood pressure." J Human Hyperten 2001;
15(4): 263 - 269. |
| [3] |
Rosenthal T, Alter A,
Peleg E, Gavish B. "Device-guided breathing
exercises reduce blood pressure and ambulatory and
home measurement." Am J Hyperten 2001; 14(1): 74 -
76. |
| [4] |
Giannattasio C, Failla M,
Meles E, Gentile G, Grappiolo A and Mancia G
“Efficacy of self treatment of hypertension at home
with device-guided breathing.” Am J Hyperten 2002;
15(4,2)186A. |
| [5] |
Elliott W, Izzo J, Rosing
D, Snyder C, White W, Alter A, Gavish B, and Black B
“Hypertension reduction by device-guided breathing
shows a dose-response relationship.” Am J Hyperten
2002; 15(4,2)186A. |
|
 |